Idenix Pharmaceuticals Inc.
60 Hampshire Street
Cambridge,
MA 02139
United States - Map
Phone: 617-995-9800
Fax: 617-995-9801
Web Site: http://www.idenix.com
| Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. The companys primary product includes Tyzeka/Sebivo for the treatment of hepatitis B virus. It also develops IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for the treatment of human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS). In addition, Idenix Pharmaceuticals, Inc. focuses on the development of drugs for the treatment of hepatitis C virus. It has a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize its NNRTI compounds, including IDX899 for the treatment of HIV/AIDS. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts. Idenix Pharmaceuticals, Inc. is a subsidiary of Novartis Pharma AG. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Jean-Pierre Sommadossi Ph.D., 53
Founder, Chairman, Chief Exec. Officer and Pres |
N/A
| N/A | Mr. Ronald C. Renaud Jr., 40
Chief Financial Officer, Principal Accounting Officer and Treasurer |
$
548.00K | N/A | Dr. David N. Standring Ph.D., 58
Exec. VP of Biology |
$
351.00K | N/A | Dr. Douglas L. Mayers M.D., 55
Chief Medical Officer and Exec. VP |
$
475.00K | N/A | Mr. John F. Weidenbruch , 48
Exec. VP, Corp. Sec. and Gen. Counsel |
$
452.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.49% Nasdaq 
Profile
